AZANDYNT Trademark

Trademark Overview


On Thursday, April 16, 2020, a trademark application was filed for AZANDYNT with the United States Patent and Trademark Office. The USPTO has given the AZANDYNT trademark a serial number of 88874507. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, April 13, 2021. This trademark is owned by Eli Lilly and Company. The AZANDYNT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
azandynt

General Information


Serial Number88874507
Word MarkAZANDYNT
Filing DateThursday, April 16, 2020
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, April 13, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 18, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 27, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Wednesday, April 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 13, 2021EXTENSION 1 GRANTED
Tuesday, March 30, 2021EXTENSION 1 FILED
Monday, April 12, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, March 30, 2021TEAS EXTENSION RECEIVED
Tuesday, October 13, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 18, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 18, 2020PUBLISHED FOR OPPOSITION
Wednesday, July 29, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 14, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 8, 2020ASSIGNED TO EXAMINER
Monday, April 27, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, April 20, 2020NEW APPLICATION ENTERED IN TRAM